Biopreservation and Biobanking最新文献

This article highlights Peru's experience in establishing a national tumor bank network, serving as a model for low- and middle-income countries. Launched in 2005 at the National Institute of Neoplastic Diseases, efforts accelerated under the 2021 National Cancer Act, which formalized the National Tumor Bank and its integration with the National Oncology Network. This initiative connects tumor banks across regional cancer institutes, enabling systematic biological sample collection, particularly from underrepresented populations, such as those with high Amerindian ancestry. Ethical oversight, technical standards, and specialized management software ensure efficient data sharing and genomic research. The network supports cancer research through integration with the Population Cancer Registry, providing unique insights into cancer incidence and outcomes. To date, 5992 cases have been documented. Through international collaboration with Latin American countries, Peru provides a framework for inclusive cancer research, enriching global genomic datasets and strengthening research capacity in diverse and vulnerable populations.

Introduction: Biobanks (BBs) are essential for biomedical research and biodiversity conservation. The Misionero Institute of Biodiversity (IMiBio), located in Misiones, Argentina, is dedicated to preserving the Atlantic Forest through a One Health approach, integrating human, animal, and environmental health. During the COVID-19 pandemic, one of its laboratories was adapted for diagnostic testing, leading to the establishment of a landmark repository of viral extracts of global significance. In addition, IMiBio contributed to the detection of SARS-CoV-2 in wildlife, expanding its BB and strengthening epidemiological surveillance efforts. This growth brought significant challenges in standardization and management. This article examines the institute's evolution, achievements, and post-pandemic perspectives. Materials and Methods: Sample processing is carried out in laboratories corresponding to the specific type of sample received, where they are prepared for entry into the BB. The BB is equipped with -20°C freezers, -80°C ultra-low temperature freezers, and liquid nitrogen tanks to ensure proper preservation of the samples. Results: The BB of IMiBio initially began by storing samples from wild animals obtained through the Güirá Oga Wildlife Rescue Center (GO). Between 2020 and 2024, the BB integrated over 7,696 samples; 43.98% of BB's storage capacity was utilized. The BB now includes RNA from SARS-CoV-2, arboviruses (dengue and chikungunya), respiratory viruses (influenza, respiratory syncytial virus), DNA from human papillomavirus, and tissue samples and microbial isolates from collaborative research. These additions reinforced BB's role in regional epidemiological surveillance but highlighted challenges in maintaining its original biodiversity focus. Conclusions: The IMiBio BB has evolved from a biodiversity repository to include biological samples derived from human diagnostics, particularly SARS-CoV-2, thereby strengthening its role in epidemiological surveillance. However, this expansion necessitates balancing its collections to ensure that its original mission of biodiversity conservation is not compromised. A strategic infrastructure expansion is planned for 2025 to enhance capacity, safety, and services.

Introduction: Incident reporting systems are vital tools for enhancing safety, quality, and continuous improvement in biomedical and health care environments, yet they remain underdeveloped within biobanking, a sector characterized by complexity, high reliability, and multidisciplinary operations. This article addresses the implementation of incident management (IM) and corrective action/preventive action (CAPA) frameworks in biobanks, with a focus on minor- to mid-level incidents and nonconformities. Methods: We conducted a structured literature review using PubMed, Google Scholar, and ResearchGate resources and distinctive keywords or keyword combinations. Relevant articles were screened across biomedical, laboratory safety, and high-reliability domains. In addition, case studies from the literature and operational experiences in biobanks were analyzed, focusing on frequent but underreported incidents. Results: Findings indicate that robust IM and CAPA adoption align with the level of quality management system (QMS) implementation. Case studies highlighted the role of psychosocial factors-such as psychological safety, trust, and nonpunitive reporting-in addition to technical processes like root cause analysis. Effective IM is demonstrated to require more than formal structures; it depends on fostering psychological safety and a trust-based "Restorative Just" culture. Conclusion: We provide the first synthesis of challenges, best practices, and cultural adaptations for IM in biobanking. For the first time, our article provides a thorough synthesis of current challenges, best practices, and cultural adaptations needed to handle incidents, and also a practical toolkit consisting of clear definitions, incident categories, and an implementation guideline to develop efficient nonconformity management in biobanking.

Collaboration between biobanks and research teams is essential for advancing scientific research, particularly in studies involving human subjects; however, various challenges can hinder success. We shed light on key obstacles and challenges encountered during a partnership between a clinical trial and an institutional biobank at a pediatric hospital. In aiming to recruit pediatric biobank participants for a genomic clinical research study, key challenges included low-yield recruitment tactics, independent operations and structures of the biobank and research teams, and transition to a new biobank model resulting in struggles with participant reengagement. This article explores some of the obstacles experienced by the research and biobanks teams, while providing key lessons aimed at guiding others in planning future collaborations for trial recruitment, enrollment, and implementation. We also highlight the significant benefits that can arise when biobanks and research teams work together strategically.

Introduction: Sperm cryopreservation is a vital tool for long-term preservation of genetic material, enabling the maintenance and transfer of genetic traits through assisted reproductive technologies. Objectives: This study aimed to assess the effects of incorporating Lactobacillus plantarum secretions (LS) into the cryopreservation protocol of goat semen. Materials and Methods: LS was added to semen extenders at concentrations of 20, 40, 60, 80, and 100 µL/mL. The control group received no additive. After freezing and thawing, various sperm quality parameters were evaluated. Results: The LS20 group showed significantly higher (p <0.05) total sperm motility compared with LS100, LS80, and the control. Progressive motility and straight-line velocity (VSL) were also improved in LS20 relative to LS100, though not significantly different from the control. LS20 demonstrated significantly higher amplitude of lateral head displacement (ALH) than the control, LS60, LS80, and LS100. LS40 also outperformed LS60-LS100 in ALH. Sperm viability was significantly increased in LS20 and LS40 compared with the control, LS80, and LS100. The sperm chromatin dispersion assay revealed significantly greater halo-to-core ratios in LS20 and LS40. Additionally, malondialdehyde levels, as a marker of oxidative stress, were markedly reduced in LS20 and LS40 compared with all other groups. Conclusions: Lower concentrations of LS, particularly 20 and 40 µL/mL, significantly improve sperm motility, viability, chromatin integrity, and oxidative status after thawing. These findings support the potential application of LS as an effective additive to enhance goat semen cryopreservation outcomes.

Background: The National Cancer Institute's Cancer Moonshot Biobank (CMB) aims to accelerate research on tumor sensitivity and resistance to standard-of-care therapies through collection and distribution of longitudinal biospecimens donated by research participants with cancer. Since low participation among historically underserved populations limits the generalizability of research done with biospecimens, CMB supports local community engagement activities. Objectives: We assessed the factors for enrollment in CMB and related precision oncology trials among rural, low-income adults with cancer who are served by the multi-site MaineHealth Cancer Care Network (MHCCN). We sought to address barriers thus identified. Methods: From October 2021 to May 2022, semi-structured interviews with MHCCN clinical research coordinators (4), oncologists (6), and patients (15) elicited perceived facilitators and barriers to participating in CMB and related trials for low-income rural Mainers. We developed a descriptive model of the steps by which patients become CMB participants based on reports from research coordinators. Factors impacting recruitment were identified at each step. Results: Rural clinics have limited staff to monitor patient lists and collect samples. Many oncologists were skeptical of clinical benefit and correspondingly reluctant to recruit vulnerable patients. Patients were generally open to CMB if recommended by their oncologist but expressed concerns that involvement in CMB or related research would consume limited time, lead to another biopsy, or threaten privacy. Conclusion: Addressing barriers for low-income, rural residents improves access for everyone. To reduce staff burden within a health system, better resourced sites can provide infrastructure and personnel support to sites with fewer resources. Education may correct misunderstandings and improve awareness of the benefits of CMB and related research involvement among research staff, oncologists, and patients.

Background: Biobanks often lack standard mechanisms to keep donors connected to their biospecimens, reflecting a broken feedback loop that compromises trust, engagement, and scientific progress. Decentralized biobanking empowers patients to track their donations throughout the research journey, supporting personalized feedback and research collaboration via a privacy-preserving blockchain network. This case study explores operational feasibility of implementing decentralized biobanking for a large breast cancer biobank at a US academic medical center. Methods: A mixed-methods case study of the groundwork, implementation, and stakeholder feedback for a real-world decentralized biobanking app pilot was conducted. Biobank members were recruited from February to April 2023. Operational feasibility was assessed via analysis of institutional stakeholder perspectives, pilot engagement, and de-bi app activity. Findings: Physicians and other biobank stakeholders surfaced challenges surrounding managing expectations, balancing empowerment with clinical and research workflows, and navigating power dynamics between patients, physicians, scientists, and leadership. A total of 1080 participants enrolled over 10 weeks, including nearly 10% of the biobank with about 4000 biospecimens. During the pilot, biobank enrollment increased 65% versus the prior year, and there were no biobank withdrawals during or within 1 year following the pilot (p < 0.001 for both). The app, which facilitated biospecimen tracking and research engagement, was downloaded by 405 users. A total of 140 users tested the blockchain component, with 89% successfully claiming a nonfungible token representing their unique, immutable connection and access to donated biospecimens. Feedback was solicited to inform potential process improvements and risk assessments related to public relations, systems infrastructure, and ethical governance, illuminating next steps. Conclusions: We established operational feasibility for the first step toward decentralized biobanking, informed by requirements to manage expectations, workflows, and power dynamics. Our technical solution demonstrated robust participant engagement and compatibility with established biobanks, suggesting potential to build trust and align incentives and identifying next steps for communications, sustainability, and governance.

The Canadian Partnership for Tomorrow's Health (CanPath) reflects upon its original decisions around sample aliquoting strategies for its specimen inventory based on what is now commonly released to researchers. We propose an updated aliquoting strategy for new collections that balances upfront resources with volumes sought for downstream analysis. This updated aliquoting strategy will help inform teams establishing new biobanks or managing existing biobanks that are considering new collections.

Background: To systematically evaluate the long-term stability of cryopreserved RNA, we extended RNA quality monitoring in our renal biobank from 7 to 11 years for samples stored in PAXgene® Blood RNA tubes at -80°C. Materials and Methods: We assessed the suitability of archived PAXgene® RNA tubes for RNA sequencing by performing quality control on 217 chronic kidney disease samples, stratified by storage duration 7 (n = 62), 9 (n = 98), and 11 (n = 57) years. RNA was extracted from 2.5 mL whole blood using the PAXgene® Blood RNA Kit, with quality assessed based on concentration (Qubit™ Fluorometer, yield), purity (NanoDrop™ 2000 spectrophotometer, A_260/A280 and A_260/230 ratios), and integrity (Agilent 2100 Bioanalyzer, RNA integrity number, RIN). Sequencing eligibility required ≥500 ng total RNA and RIN ≥6.0. Results: Median RNA yields were comparable across storage durations (7-year 7.00 µg, 9-year: 7.11 µg, and 11-year: 6.79 µg, p = 0.870). The median A_260/280 ratios were 2.03 (7-year), 2.08 (9-year), and 2.07 (11-year) (p < 0.001, all ≥1.8), while median A_260/230 ratios were 1.72, 1.77, and 1.87, respectively (p = 0.550). RNA integrity, as measured by RIN, showed median values of 8.90 (7-year), 9.00 (9-year), and 8.80 (11-year). While no significant differences were observed between the 7- and 9-year (p = 0.537) or 7- and 11-year groups (p = 0.052), the 9-year group had slightly higher RIN values than the 11-year group (p < 0.05). Sequencing suitability remained consistently high (7-year: 97%, 9-year: 98%, and 11-year: 98%, p = 0.750), with 98% (212/217) of samples meeting the standards. Even under stricter RIN thresholds, pass rates remained robust (RIN ≥ 7.0: 94%, RIN ≥ 8.0: 88%). Conclusion: PAXgene® Blood RNA tubes stored at -80°C for up to 11 years provide high-quality RNA suitable for total RNA sequencing.

Introduction: Optimal cryopreservation of testicular tissue is essential for species research and conservation, enabling long-term storage of genetic resources through vitrification or slow freezing. Comparing responses from different taxonomic groups to these techniques is crucial for refining protocols and improving cryopreservation outcomes. Objectives: This study evaluated the effects of cryopreservation on cell viability, morphology, mitochondrial activity, and proliferative potential to optimize testicular tissue preservation strategies for wildlife conservation. Methods: We assessed testicular tissue from Felidae and Cervidae, including domestic cats (Felis catus) and Neotropical deer species, white-tailed deer (Odocoileus virginianus), Brazilian red brocket deer (Mazama nana), and gray brocket deer (Subulo gouazoubira). Experimental groups included control (no cryopreservation), slow freezing using Mr. Frosty or progressive temperature decrease, and conventional vitrification. Results: All methods preserved live cells and normal tissue morphology; however, compared with fresh tissue, cryopreservation significantly reduced tissue viability, mitochondrial membrane potential, and the proportion of intact seminiferous tubules. Species-specific differences emerged, with vitrification being most effective for domestic cats, while slow freezing yielded better results for Neotropical deer. Despite lower viability scores, vitrification could still be an acceptable option for cervids due to its rapid processing and minimal equipment requirements. In addition, post-cryopreservation tissue culture increased cell abnormalities, highlighting the need to optimize culture conditions for different species. Conclusion: This comparative study advances reproductive tissue preservation techniques and emphasizes the importance of tailored cryopreservation as well as in vitro culture protocols for diverse taxonomic groups.